IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Other Versions of this Article:
IAI.01184-06v1
75/3/1089    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, V. T.
Right arrow Articles by Lory, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, V. T.
Right arrow Articles by Lory, S.
Infection and Immunity, March 2007, p. 1089-1098, Vol. 75, No. 3
0019-9567/07/$08.00+0     doi:10.1128/IAI.01184-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Pseudolipasin A Is a Specific Inhibitor for Phospholipase A2 Activity of Pseudomonas aeruginosa Cytotoxin ExoU{triangledown} ,{dagger}

Vincent T. Lee,1* Stefan Pukatzki,1 Hiromi Sato,4 Eriya Kikawada,2 Anastasia A. Kazimirova,1 Jin Huang,1 Xiaohua Li,3 Jonathan P. Arm,2 Dara W. Frank,4 and Stephen Lory1

Department of Microbiology and Molecular Genetics, Harvard Medical School,1 Dana Farber Cancer Institute, Boston, Massachusetts 02115,2 Broad Institute, Cambridge, Massachusetts 02142,3 Department of Microbiology and Molecular Genetics, Medical College of Wisconsin, Milwaukee, Wisconsin 532264

Received 28 July 2006/ Returned for modification 11 October 2006/ Accepted 9 December 2006

A number of bacterial pathogens utilize the type III secretion pathway to deliver effector proteins directly into the host cell cytoplasm. Certain strains of Pseudomonas aeruginosa associated with acute infections express a potent cytotoxin, exoenzyme U (ExoU), that is delivered via the type III secretion pathway directly into contacting host cells. Once inside the mammalian cell, ExoU rapidly lyses the intoxicated cells via its phospholipase A2 (PLA2) activity. A high-throughput cell-based assay was developed to screen libraries of compounds for those capable of protecting cells against the cytotoxic effects of ExoU. A number of compounds were identified in this screen, including one group that blocks the intracellular activity of ExoU. In addition, these compounds specifically inhibited the PLA2 activity of ExoU in vitro, whereas eukaryotic secreted PLA2 and cytosolic PLA2 were not inhibited. This novel inhibitor of ExoU-specific PLA2 activity, named pseudolipasin A, may provide a new lead for virulence factor-based therapeutic design.

* Corresponding author. Present address: Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742. Phone: (301) 405-9397. Fax: (301) 314-9489. E-mail: vtlee{at}umd.edu.

{dagger} Supplemental material for this article may be found at http://iai.asm.org/.

{triangledown} Published ahead of print on 18 December 2006.

Editor: V. J. DiRita

Infection and Immunity, March 2007, p. 1089-1098, Vol. 75, No. 3
0019-9567/07/$08.00+0     doi:10.1128/IAI.01184-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2007 by the American Society for Microbiology. All rights reserved.